The selective pan-Akt inhibitor ipatasertib (GDC-0068) is being tested in combination with pertuzumab and trastuzumab in BC patients with advanced HER2+ PI3KCA mutation [NCT04253561]. This evidence concerns the gene ERBB2 and breast cancer.